QUANTUMONLINE.COM SECURITY DESCRIPTION:  Cyclacel Pharmaceuticals Inc., formerly Xcyte Therapies Inc., 6% Convertible Exchangeable Preferred Stock, liquidation preference $10 per share, redeemable at the issuer's option on or after 11/06/2007 at 104.2% of the liquidation price which declines to 100% by 11/1/2014 (see the schedule on page 98 of the prospectus), with no stated maturity, and with cumulative distributions of 6% ($0.60) per annum paid quarterly on 2/1, 5/1, 8/1 & 11/1 to holders of record on the date fixed by the board, not more than 60 days or less than 10 days prior to the payment date (NOTE: the ex-dividend date is one business day prior to the record date). The preferred shares are convertible any time at the holder's option into 4.2553 common shares of Xcyte Therapies Inc. (Nasdaq: XCYT), an initial conversion price of $2.35 per common share. See the note below for information on the effect of the 1 for 10 reverse stock split on the conversion rate. If the price of the common stock exceeds $3.53 for 20 of any 30 consecutive trading days, the company may, at their option, force the preferred shares to be converted into common shares at the then prevailing conversion price. Dividends paid by this preferred security are eligible for the preferential income tax rate of 15% to a maximum of 20% depending on the holder's tax bracket (and under IRS specified holding restrictions) and are also eligible for the dividends received deduction for corporate holders. In regards to payment of dividends and upon liquidation, the preferred shares rank equally with other preferreds and senior to the common shares of the company. See the IPO prospectus for further information on the convertible preferred stock and the conversion provisions by clicking on the ‘Link to IPO Prospectus’ provided below.

Stock Exchange	Cpn Rate Ann Amt	LiqPref CallPrice	Call Date Matur Date	Moodys/S&P Dated	Conv Shrs Conv Price	Distribution Dates	15% Tax Rate
NCM Chart	6.00% $0.60	$10.00 $10.00	11/01/2014 None	NF NF 4/16/2023	0.42553 $23.50	2/1, 5/1, 8/1 & 11/1 Click for MW ExDiv Date Click for Yahoo ExDiv Date	YES

Notes:  From the 10-K Annual Report filed with the SEC on 3/31/2011 -- On February 1, 2011, we paid a quarterly cash dividend in the amount of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock. The dividend was paid to the holders of record of the Preferred Stock as of the close business on January 21, 2011. ____________ April 8, 2009 -- Cyclacel Pharmaceuticals, Inc. announced that its Board of Directors passed a resolution to suspend payment of but continue to accrue the quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock. Following this measure, along with previously announced reductions in expenditure, the Company projects its cash resources are sufficient to fund operations into the second quarter of 2010. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on a quarterly basis. ____________ From page 86 of the 10-K Annual Report filed with the SEC on 3/13/2008: The Preferred Stock is convertible at the option of the holder at any time into the Company’s common stock at a conversion rate of approximately 4.2553 shares of common stock for each share of Preferred Stock, based on an initial conversion price of $2.35. The initial conversion price is subject to adjustment in certain events, including the one for ten reverse stock split of Xcyte’s common stock pursuant to which the conversion price of the convertible preferred stock now equals approximately $23.50. Such adjusted conversion price is equivalent to a conversion rate of approximately 0.42553 shares of common stock for each share of convertible preferred stock. ____________ March 28, 2006 -- Cyclacel Group plc announced today that it has completed the previously announced transactions with Xcyte Therapies, Inc. In connection with the closing, the previously announced one-for-ten reverse stock split was completed before the opening of the market on March 27, 2006 and the combined company was renamed Cyclacel Pharmaceuticals, Inc.. Cyclacel is focused on the discovery and development of small molecule cell cycle inhibitors for the treatment of cancer and other serious diseases. Currently the company has two drugs, seliciclib (CYC202) and sapacitabine (CYC682), in clinical trials for the treatment of cancer, a third compound in late preclinical development, a large pipeline of development candidates, and a productive drug discovery engine. The new company has approximately 9.7 million common shares following the reverse stock split and approximately 2.0 million preferred shares outstanding which would be equivalent to 0.9 million shares of common stock if converted. Cyclacel has approximately $30 million in cash and marketable securities. Cyclacel common stock is expected to begin trading on the Nasdaq National Market under the ticker symbol CYCC on March 28. Cyclacel preferred stock is expected to begin trading on the Nasdaq Capital Market under the ticker symbol, CYCCP.

Company's Online Information Links

HOME PAGE:     https://www.cyclacel.com/
Company's Investor Relations Information	Go to Investor Relations Information
Company's Online News Releases	Go to News Releases
Online Company Profile	Go to Online Profile

Company's Online SEC EDGAR Filings

Company's SEC EDGAR Filings

Go to SEC Filings

Company's Email Address Links

Inv Rel Email Address	pmcbarron@cyclacel.com
General Email Address	info@cyclacel.com
Email Request Form on Website	Go to Email Form

Address and Phone Numbers

Address:   200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922
Main Phone Number	908-517-7330
Fax Number	866-271-3466
Investor Contact (CFO)   Paul McBarron	908-517-7330
Toll Free Phone Number	Unknown

CEO - Spiro Rombotis

CFO - Paul McBarron